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Abstract
Background: Annually in the US, over 100,000 pregnant women with overt type 2 diabetes give birth. Strict maternal
glycemic control is the key to optimizing infant outcomes. Medical treatment of type 2 diabetes in pregnancy is
generally restricted to insulin, as data on the safety and efficacy of oral hypoglycemic agents in pregnancy are limited.
However, over one-third of infants born to women with type 2 diabetes experience an adverse outcome, such as
premature delivery, large-for-gestational age, hypoglycemia, hyperbilirubinemia, or birth trauma, suggesting that current
treatment regimens fall short of optimizing outcomes. Metformin is the pharmacologic treatment of choice for type 2
diabetes outside of pregnancy. Metformin is favored over insulin because it results in less weight gain, fewer
hypoglycemic episodes, and is administered orally rather than injected. However, metformin is not typically used for
treatment of type 2 diabetes complicating pregnancy, mainly because no large clinical studies have been conducted to
examine its use in this context.
Methods/design: This is a randomized double-blind multi-center clinical trial of insulin plus metformin versus insulin
plus placebo for the treatment of type 2 diabetes complicating pregnancy. A total of 1200 women with type 2
diabetes will be randomized between 10 weeks 0 days’ and 20 weeks 6 days’ gestation and followed until 30 days after
delivery. Neonate outcomes will be followed until 30 days of age. The primary aim is to compare the effect of insulin
and metformin versus insulin and placebo on composite adverse neonatal outcomes, comprising perinatal mortality,
preterm delivery, neonatal hypoglycemia, hyperbilirubinemia, large-for-gestational age small for gestational age, low
birth weight, and/or birth trauma. Key secondary aims are to compare treatment groups for neonatal fat mass and rate
of maternal hypoglycemia. Additional aims are to assess the side effects and safety of insulin and metformin among
pregnant women with overt type 2 diabetes and to compare gestational weight gain among women treated with
metformin plus insulin versus insulin alone.
Discussion: Successful completion of this study will result in high-quality, contemporary evidence for management of
overt type 2 diabetes complicating pregnancy to improve neonatal outcomes.
Trial registration: NCT02932475 (05/17/2016).
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Background
Type 2 diabetes mellitus (T2DM) is the most common
type of diabetes [1]. In the United States (U.S.), T2DM
affects approximately 29.1 million people (9.3%), and, of
those 29.1 million, 21.0 million are diagnosed and 8.1
million are undiagnosed [1]. Approximately two million
women of reproductive age have T2DM [1]. Annually in
the U.S. T2DM affects approximately 100,000 pregnan-
cies [2]. By 2030, the number of women entering preg-
nancy with T2DM is expected to double [2]. T2DM is
the most common type of overt diabetes complicating
pregnancy and is a serious public health concern [1, 2].
As the physiologic changes in pregnancy are designed
to supply glucose to the fetus and placenta, the pregnant
state promotes maternal insulin resistance [3]. In the
second half of gestation, the fetus grows several-fold in
size, and the absolute of glucose utilization increases
substantially [3]. Placental glucose transfer increases sec-
ondary to the increasing metabolic requirements of the
fetus [3]. Also, placental hormones increase the transpla-
cental glucose concentration gradient, increasing the
maternal glucose concentration relative to the fetus [3].
Increasing insulin resistance and transient hypoglycemia
between meals and at night due to continuous fetal draw
sets the stage for transient postprandial hyperglycemia
after meals [3]. Therefore, insulin resistance in T2DM
significantly complicates pregnancy, and optimal mater-
nal glucose control is challenging.
Type 2 diabetes is associated with significant maternal
and infant morbidity [2]. Type 2 diabetes in pregnancy is
associated with adverse pregnancy outcomes, including
miscarriage, congenital birth defects, fetal growth dis-
turbance (under and over), preterm birth, preeclampsia,
and stillbirth [2]. Complications associated with T2DM
in pregnancy include preeclampsia (20%), early delivery
secondary to medical necessity or spontaneous preterm
birth (33%), and small or large-for-gestational age (LGA)
infants (30%) [2]. Also, T2DM is associated with fetal
programming of obesity and T2DM later in life [2].
Therefore, it is advantageous to maintain euglycemia to
prevent fetal overgrowth. However, knowledge gaps exist
regarding optimal therapy in pregnant women with overt
T2DM to reduce morbidity.
The American Diabetes Association (ADA) [1] and the
American Association of Clinical Endocrinologists [4]
recommend that metformin therapy in the absence of
contraindications be initiated with lifestyle intervention
at the time of T2DM diagnosis. Metformin has excellent
glycemic efficacy, offers decreased weight gain and de-
creased hypoglycemic episodes, and is well tolerated and
reasonably priced [5].
Current recommendations for medical management of
T2DM in pregnancy include frequent blood glucose
monitoring combined with dietary management and
insulin therapy to achieve euglycemia [1, 2]. However,
use of oral hypoglycemic agents in gestational diabetes
mellitus (GDM) has recently gained acceptance [6]. The
efficacy of metformin for treatment of GDM was found
to be comparable to insulin and had fewer side effects
and increased patient preference [6]. Rowan and col-
leagues [7, 8] found that, in women with GDM, metfor-
min alone or in combination with insulin was not
associated with an increase in perinatal complications
when compared to insulin alone. There were signifi-
cantly fewer maternal hypoglycemic events (p = 0.008)
and less maternal weight gain (p < 0.001) in women
treated with metformin compared to insulin alone [7].
Also, a 2-year follow-up of infants of mothers enrolled
in the study demonstrated no adverse effects and a re-
duction of visceral body fat [9]. In a retrospective,
case-controlled study of women with T2DM, the re-
searchers found comparable outcomes between women
treated with metformin versus insulin [8, 10].
Aims
The aims of this study are to compare the effectiveness
and safety of insulin mono-therapy versus insulin plus
metformin for treatment of T2DM complicating preg-
nancy. The primary study outcome is a composite ad-
verse neonatal outcome, defined as the proportion of
infants who have one or more of the following condi-
tions at birth: 1) neonatal hypoglycemia, defined as a ca-
pillary blood glucose (CBG) < 40 or any hypoglycemia
that requires intravenous (IV) fluid treatment; 2) birth
trauma, defined as umbilical artery cord pH < 7.0, shoul-
der dystocia with either brachial plexus injury, clavicular
fracture, humeral fracture, and/or > 3 maneuvers to re-
lieve. Additional adverse neonatal outcomes include 3)
hyperbilirubinemia that required infant phototherapy
within the first 72 h after delivery; 4) delivery < 37 weeks’
gestation; 5) miscarriage (fetal loss < 20 weeks); 6) still-
birth (fetal loss > 20 weeks); 7) neonatal death (death
prior to 28 completed days); 8) large-for-gestational age
infant (birthweight >90th percentile for gestational age
[GA]); and 9) small-for-gestational age (SGA) infant
(birthweight <10th percentile for GA) or low birth
weight (< 2500 g [gm]). In cases for which classification
of the primary outcome is not straightforward, event sta-
tus will be adjudicated by two independent members of
an adjudication committee, with further review by a
third member in the case of discordance.
There are two key secondary outcomes. The first is in-
fant fat mass (%), as measured by anthropometrics. Birth
weight, recumbent length, and head circumference will
be abstracted from the chart. Right upper mid-arm cir-
cumference, right triceps, subscapular, and flank skin-
folds will be measured by the study staff. The second is
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clinically relevant maternal hypoglycemia (CBG < 60) re-
gardless of the presence of symptoms.
Additional exploratory secondary outcomes for the
mother include maternal weight gain, defined as a change
in weight from randomization until time of delivery,
adjusted for GA at time of randomization; maternal
side-effects such as nausea, vomiting, and diarrhea; mater-
nal compliance determined by pill counts; maternal
intention to breast or formula feed; adverse maternal out-
comes including death, diabetic ketoacidosis, intensive
care unit (ICU) admission, intubation, or renal failure; and
maternal obstetrical complications including placental
abruption or preeclampsia. Exploratory secondary out-
comes for the neonate include neonatal metabolic compli-
cations other than hypoglycemia or hyperbilirubinemia,
including polycythemia, neonatal intensive care unit
(NICU) admission > 48-h length of stay, hyperbilirubine-
mia requiring phototherapy, intubation, or grade 3 or 4 in-
traventricular hemorrhage (IVH); and postpartum feeding
experience at 30 days.
Additional study outcomes include measurement of
maternal metabolic markers at 24–30 weeks’ gestation.
One 10ml (ml) tube of blood will be collected and cen-
trifuged, and resultant serum will be frozen at − 80 °C
for future analyses. Biomarkers planned to be measured
include, but are not limited to, soluble fms-like tyrosine
kinase-1, placental growth factor, leptin, and C-peptide.
Other analyses will assess the role and interactions of
clinical, biological, and biophysical factors on the occur-
rence and severity of maternal and neonatal outcomes.
Methods
Design
This is a phase III randomized double-blind clinical trial
of insulin plus placebo versus insulin plus metformin for
the treatment of overt T2DM complicating pregnancy.
Women 10 weeks 0 days’ and 20 weeks 6 days’ gestation
will be randomized and followed until 30 days after de-
livery. Neonate outcomes will be followed until 30 days
of age.
All study subjects will receive standard surveillance and
treatment for overt T2DM in pregnancy, which may in-
clude, but will not be limited to, a daily prenatal vitamin,
supplemental folic acid, nutritional counseling and dietary
recommendations, and insulin therapy as prescribed by
their primary clinician (e.g., obstetrician or endocrinolo-
gist). The decision of the primary clinician on insulin dos-
ing will be guided by standard guidelines based on the
protocols that are used at the participating clinical trial
centers. Instructions on capillary glucose monitoring will
include a recommendation to test CBG at least four times
a day. The goal of CBG parameters will be communicated
to the subject by her primary clinician. The subject’s pri-
mary clinician will make adjustments to insulin dosing
based on patient-recorded CBG measurements. Blood and
urine sampling for hematologic, liver, and kidney function
will occur at the primary obstetric clinician’s discretion.
Likewise, ultrasound assessments of fetal size and
well-being will occur at the primary obstetric clinician’s
discretion. Fetal surveillance by nonstress test (NST; 30
min of continuous fetal heart rate monitoring) or biophys-
ical profile (BPP; 30min of ultrasound to monitor for fetal
breathing, movement, flexion/extension, and amniotic
fluid) will also occur at the primary obstetric clinician’s
discretion. Routine care in labor and delivery will include,
but will not be limited to, insulin therapy. Subjects will be
instructed to hold the oral study agent (metformin or pla-
cebo) at the onset of labor, at induction of labor, or on the
morning of a scheduled cesarean delivery. No metformin
will be administered during labor or in anticipation of a
scheduled cesarean delivery, when patients are asked to
ingest nothing by mouth (NPO) for 12 h prior to the
procedure.
Guidelines for insulin management have been created
based on current strategies used at the study sites. Insu-
lin dosing will be weight-based and administered as two
to three daily injections. Insulin dose adjustments will be
made at the discretion of the study site’s primary clin-
ician using glycemic goals that are based on the ADA
guidelines (Table 1). Women will test CBG levels daily
while fasting and either 1 or 2 h postprandial, per the
protocol at each clinical site, with goals listed in Table 2.
The primary clinician will manage insulin dosing to
achieve these goals as closely as possible.
In addition to the standard care described above, en-
rolled and randomized subjects will receive surveillance
and treatment solely for study purposes. Women will be
instructed to stop any other diabetes or oral hypoglycemic
(OHA) medication and begin and/or continue insulin. All
subjects will begin taking the study agent with the evening
meal the day after randomization. This allows those who
have been taking an oral agent previously to have at least
a 24-h washout period. Daily administration of the study
agent will be as follows: one capsule (metformin 500mg
or placebo) twice daily for 7–21 days based on study agent
tolerance, followed by two capsules (metformin 1000mg
or placebo) twice daily. Drug tolerance is defined as the
subject’s reported tolerance of the symptoms of nausea,
vomiting and/or diarrhea and fewer than two episodes of
self-reported hypoglycemia as manifested by a CBG < 60
mg/dL. Subjects will be instructed how to manage symp-
toms at home, including taking the study agent with meals
and using over-the-counter medications to relieve
Table 1 MOMPOD Study Insulin Dosing Guidelines by Trimester
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symptoms such as nausea and diarrhea. If the subject has
two or more self-reported hypoglycemia episodes (CBG <
60mg/dL), she will be instructed to call her provider. Sub-
jects will be instructed to increase the study agent after 7
days if they are tolerating the lower dose. If not, subjects
will remain on the lower dose for up to three seven-day pe-
riods. Once increased to two capsules twice daily, the sub-
ject will be contacted weekly to determine tolerance at the
higher dose. If the subject is unable to tolerate the study
agent after a maximum of 21 days at either dose, she will
be discontinued from the study agent. All subjects who dis-
continue the study agent will be followed through delivery.
If the subject reports intractable gastrointestinal (GI)
symptoms or hypoglycemia during the phone calls to as-
sess study agent tolerance, study staff will educate the
subject on timing for taking the agent with food and will
remind her of the medications she can use to relieve
symptoms. If she experiences hypoglycemia, study staff
will instruct her to contact her primary clinician to
evaluate whether insulin dosing needs to be adjusted. In-
tractable symptoms are defined as any nausea, vomiting,
or diarrhea despite the use of medications to decrease
these symptoms. Study visits will coincide with prenatal
visits to assess compliance and side-effects and dispense
the study agent. Study visits are to occur every 4 weeks
during selected, regularly scheduled, prenatal visits. Tim-
ing of study visits may vary based on the patient’s pre-
natal visit schedule, and can occur as often as once
every 3 weeks. Study visits must occur at least once each
30 days.
Blood will be drawn at 24–30 weeks’ gestation to store
serum for future studies. Chart abstraction will be con-
ducted for maternal and delivery data (up until maternal
discharge) and neonatal data (up until infant discharge
or until 30 days of age, whichever comes first). Within
72 h of delivery, measurement of neonatal fat mass (i.e.,
anthropometrics) by skinfold caliper will be completed
unless the infant is < 28 weeks’ gestation or the infant’s
condition is unstable. Phone call or in-person contact
with the mother after 30 days following delivery will be
made to assess for serious adverse events and neonatal
outcomes. The contact must be made within 45 days of
delivery.
Settings
The study is being conducted in partnership with Uni-
versity of North Carolina at Chapel Hill (UNC-CH)
Women’s Clinic and Hospital, the Clinical Coordinating
Center (CCC), UNC-CH Collaborative Studies Coordin-
ating Center (CSCC), and Data Coordinating Center
(DCC) all located in Chapel Hill, North Carolina as well
as at the following sites: The Ohio State University at
Columbus, Ohio; University of Pennsylvania, Philadelphia,
Pennsylvania; University of California, San Diego Maternal
Fetal Care Services and the Medical Offices South
Women’s Health Services, San Diego, California; Univer-
sity of Alabama-Birmingham, Birmingham, Alabama; Uni-
versity of Utah Health Sciences Center, including the LDS
Hospital, McKay-Dee Hospital Center, Utah Valley Re-
gional Medical Center, and the Intermountain Medical
Center in Salt Lake City, Utah; University of Texas Med-
ical Branch, Galveston, Texas; University of Texas Me-
morial Hermann Hospital and the LBJ Hospital Houston,
Houston, Texas; and Columbia University, New York,
New York.
Power analysis
We plan to randomize 1200 women. A 10% loss to
follow-up will leave 1080 subjects with complete data
and follow-up (540 per arm). We expect an additional
5–10% of subjects will discontinue the study agent for
various reasons, including side-effects or intolerance, but
will contribute follow-up data. This sample size gives ad-
equate power over a range of expected primary outcome
event rates, with type I error set at 0.044 (reduced from
0.05 for interim analysis), and maintains reasonable
power under a conservative scenario, assuming that 10%
of subjects immediately stop taking the study agent.
Published data suggest that up to 30% of pregnant
women with T2DM have an adverse neonatal outcome
[11–13]. Our proposed sample size conservatively ac-
counts for the possibility that the composite adverse
neonatal outcome may be lower than anticipated. Our
approach offers at least 89% power to detect an odds ra-
tio of 0.60 for metformin versus placebo, assuming a pri-
mary outcome rate in the placebo group of 20% or
more. Other scenarios, assuming a lower primary out-
come rate in the placebo group or a smaller treatment
effect, will yield ~ 80% power to detect a treatment
difference.
Sample
Inclusion criteria are as follows: maternal age 18–45
years old; informed verbal and written consent; singleton
fetus with no known or suspected anomalies; overt type
2 diabetes, defined as either pregestational type 2 (overt)
diabetes requiring medical treatment (e.g., oral agent or
insulin), or overt diabetes diagnosed at < 20 weeks 6
days’ gestation, using either the one-step method (75 g
glucose challenge test [GCT] with at least one abnormal
value: fasting blood glucose (FBG) > 92, 1 h > 180 or 2
h > 153 g/dl) or the two-step method (50 g GCT > 135
Table 2 MOMPOD Study Capillary Blood Glucose Goals Based
on ADA Guidelines
Fasting 1 Hour Postprandial 2 Hours Postprandial
< 95mg/dl < 140mg/dl < 120mg/dl
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mg/dl followed by 100 GCT with at least two values
above thresholds: FBG > 90, 1 h > 180, 2 h > 155, 3 h >
140 mg/dl); or other method (e.g. A1C > 6.5%, OR fast-
ing CBG > 126mg/dL, OR random CBG > 200mg/dL).
Other inclusion criteria are a willingness to use insulin
and study agent only and to use no other diabetes med-
ical therapy while in the study as well as gestational age
at randomization between 10 weeks 0 days and 20 weeks
6 days by menstrual dating confirmed by ultrasound or
ultrasound alone.
Gestational age will be determined in the following
manner and will be denoted as the study GA. The study
estimated date of confinement (EDC), which will be
based on the study GA, will not be revised once a deter-
mination has been made. If the pregnancy is conceived
by in vitro fertilization, the study GA will be calculated
from the date of embryo transfer and the embryo age at
transfer. If the pregnancy is conceived spontaneously
(including ovulation induction and artificial insemin-
ation), information from the last menstrual period
(LMP) and earliest dating ultrasound will be used to as-
sign study gestational age using the following algorithm:
the first day of the LMP will be determined and a judg-
ment made as to whether the patient has a certain LMP
date. If the LMP date is certain, study GA will be deter-
mined by a comparison between the GA by LMP and by
the earliest dating ultrasound. The first dating ultra-
sound must have been conducted before 20 weeks 6
days, by LMP. If the ultrasound confirms the GA calcu-
lated by LMP, as in Table 3, the LMP GA will be used as
the study GA. Otherwise, study GA will be determined
based upon the ultrasound measurement. If the LMP
date is uncertain, measurement(s) obtained at the pa-
tient’s first dating ultrasound examination will be used
to determine the study GA. The first dating ultrasound
must be conducted before 20 weeks 6 days’ gestation.
Multiple gestation is an exclusion criterion; however, if a
woman with a twin gestation spontaneously loses one
fetus and retains the second fetus or is electively reduced
to a singleton prior to 14 weeks, she will be eligible for
participation. Exclusion criteria also include a suspected
or known fetal structural or chromosomal abnormality,
pre-existing renal disease with creatinine > 1.5mg/dL, and
medical contraindications to metformin as evidenced by a
history of lactic acidosis. Additional exclusion criteria are
acute liver disease or known liver abnormalities, such as
acute viral hepatitis, aspartate aminotransferase, and/or
alanine aminotransferase elevated more than twice the
normal limit. Medical conditions that predispose a woman
to gastrointestinal distress, such as Crohn’s disease, ulcera-
tive colitis, irritable bowel syndrome (IBS), or celiac dis-
ease will further exclude a woman from participation in
the study, as will current or past history of alcohol abuse
and/or abnormalities in B12 metabolism, such as perni-
cious anemia, intrinsic factor deficiency, or prior partial or
complete gastrectomy. Participation in another study that
could affect primary outcome and/or randomization in
the current study during a previous pregnancy are also ex-
clusion criteria. Women will be excluded if their delivery
is planned at a location other than a study hospital, if they
are unwilling or unable to take insulin, and/or if they are
unwilling or unable to swallow the study agent capsule or
consume an inert ingredient in the study agent capsule.
Finally, women will be excluded if another significant
chronic medical or psychiatric illness would, in the inves-
tigators’ opinion, prevent participation in the study.
Staff training and monitoring proficiency
The multiple principal investigators (MPIs),
co-investigators, project coordinator, and research nurse
will train study staff on all aspects of the study protocol
(e.g., screening, recruitment, enrollment, randomization,
study visit data collection, and specimen and data collec-
tion). Training sessions to orient staff to protocol and
data collection forms will be held via webinar teleconfer-
ence. Following training, all study staff must demon-
strate proficiency in the protocol implementation as
defined in the manual of operations (MOO). Once profi-
ciency is demonstrated, individual study staff gain
password-protected access to the electronic data entry
website and can begin screening and recruitment of sub-
jects. The DCC will generate data quality queries on an
ongoing basis to inform sites of continued data collec-
tion proficiency.
One of the MPIs or her designee will train the
UNC-CH project manager and research nurse and staff
on the proper technique for infant measurements. A
webinar teleconference, relying on a standardized system
used in previous studies, will be developed for training
all of the sites. Despite offering many benefits (e.g., low
cost, easy to perform, little equipment required), an-
thropometrics are challenging, due to their vulnerability
to measurement errors and lack of reliability. Unreliabil-
ity can occur due to imprecision, such as measurement
error variance due to intra- and inter-observer variabil-
ity. Imprecision can arise from inadequate or improper
training of personnel, difficulties in measurement of cer-
tain anthropometric characteristics, such as skinfolds,
and instrumental or technical errors. We created a
step-by-step approach in the MOO for all anthropomet-
ric measurements as well as a training video to teach
Table 3 Determining Gestational Age
Gestational age at first ultrasound Ultrasound agreement with
last menstrual period
Up to 13 weeks 6 days + 5 days
14 weeks 0 days to 20 weeks 6 days + 7 days
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measurement of bicep circumference and tricep, sub-
scapular, and flank skinfolds. A duplicate measure pro-
gram was developed and sites will be chosen at random
by the DCC so that, for that entire month, all infant bi-
cep circumferences and tricep, subscapular, and flank
skinfolds will be measured by a second team member.
Inter-rater reliability will be analyzed quarterly by calcu-
lating an inter-rater reliability coefficient. This allows
timely feedback to be given to the site project coordina-
tors and research nurses, and corrective measures will
be taken quickly if reliability is not adequate.
Ethical considerations
Each study site will develop a site-specific verbal and
written consent form using the template consent form
provided by the CCC. Each site will be responsible for
obtaining Institutional Review Board approval and verbal
and written informed consent for each enrolled subject.
Each site will develop its own patient research
authorization documents, as required by the Health In-
surance Portability and Accountability Act Privacy Rule,
following the guidelines of its own institution. A copy of
the signed consent form will be provided to the enrolled
subject. A person fluent in their language will enroll
women who are not fluent in English. Both verbal and
written informed consent and authorization will be ob-
tained in that language. If this is not possible, the patient
will be excluded from participation.
Randomization and blinding
Randomization for enrolled subjects will occur at 10
weeks 0 days to 20 weeks 6 days of gestation. Enrolled
subjects will be assigned to placebo or metformin in a
1:1 ratio in a permuted block design, stratified by study
site and timing of diabetes diagnosis/baseline GA (four
categories: pre-existing diagnosis and GA < 18 weeks,
pre-existing diagnosis and GA ≥ 18 weeks, diagnosis dur-
ing pregnancy and GA < 18 weeks, diagnosis during
pregnancy and GA ≥ 18 weeks). The randomization se-
quence will be prepared and maintained centrally by the
DCC. A statistician not otherwise involved with the
study will create the randomization scheme, which will
be implemented electronically within the web-based data
management system. All study staff will be blinded to
the allocation scheme until the end of the study. Emer-
gency unblinding will be available around the clock for
designated staff through the web-based data manage-
ment system.
Intervention
All subjects will receive insulin and metformin, 500mg
twice daily, or placebo, from enrollment through the first
week (or up to 3 weeks based on tolerability), then met-
formin 1000mg or placebo twice daily until delivery. A
drug distribution center (DDC) will provide the blinded
study agent (metformin and placebo) to the research
sites. The study agent will be dispensed to subjects in a
single bottle of 120 opaque capsules containing either
500 mg metformin or placebo matched to appearance
and taste. Randomization will be performed via the
web-based data management system, and a reporting
feature within the system will indicate which bottle to
dispense to the study subject at each study visit. Study
visits are to occur at least every 4 weeks. Timing of
study visits may vary based on the patient’s prenatal visit
schedule, study visit scan occur as often as once each 3
weeks but must occur at least once each 30 days. The
study agent will be bottled in 30-day quantities. Bottles
will be labeled with the subject’s identification number.
Subjects will be instructed to take the study agent, with
food, as one capsule (500 mg metformin or placebo)
twice a day, for 7 or up to 21 days, depending on study
agent tolerance, then two capsules (1000 mg metformin
or placebo) twice a day until delivery. If they miss a dose,
subjects will be instructed to continue with dosing and
not to double up to account for the missed dose. Sub-
jects will be queried at study visits (coincident with pre-
natal visits) by study staff regarding compliance with the
study regimen. Capsule counts will be conducted at each
study visit. Independent of study participation the pri-
mary physician is responsible for all clinical treatment
decisions including insulin dosing.
Measurement
Study visits will coincide with clinical (prenatal) visits
and occur approximately every three to 4 weeks. Timing
of study visits may vary based on the patient’s prenatal
visit schedule, but study visits must occur at least once
each 30 days. At each visit, the medical record will be
reviewed for intervening problem visits, hospitalizations,
and insulin dosing adjustments, and data will be re-
corded. Staff will ask subjects about symptoms and
events since the previous visit. Blood glucose logs will be
reviewed and data abstracted (or the logs will be copied
for later abstraction), and maternal weight and blood
pressure will be recorded. Table 4 illustrates the forms
that will be completed at each study visit.
Data management
The DCC will be responsible for receiving all electronic
data from the sites. Clinical center staff will enter data
using the Carolina Data Acquisition and Reporting Tool
web-based data management system. Data editing and
validity checks and reports for missing fields are built
into the system. The DCC has created an online tutorial
to train staff on use of the data management system and
all staff will be certified on data entry prior to complet-
ing data entry for the study.
Berry et al. BMC Pregnancy and Childbirth          (2018) 18:488 Page 6 of 12
Interim analysis
We will perform a formal interim analysis to evaluate
for early overwhelming efficacy after 50 and 75% of sub-
jects have delivered and completed follow-up. We will
also perform a formal interim analysis to evaluate for fu-
tility after 75% of subjects have delivered and completed
follow-up. To assess early efficacy, the significance level
for the interim and final analysis will be based on a
Lan-DeMets α-spending function with O’Brien-Fleming
boundaries in order to maintain the study-wise α level at
0.05. The α level will be 0.0031 at 50%, 0.0183 at 75%,
and 0.044 at the final analysis. The exact α level at the
interims will be determined based on the actual percent
of data available at the interim. Assuming 90% power at
the end of the study, there is a 26% chance of meeting
the stopping boundary at the first interim and a 69%
chance of meeting the stopping boundary at the second
interim. Futility will be assessed at 75% based on condi-
tional power. The Data Safety Monitoring Board
(DSMB) may recommend that the study stop due to
futility if the upper limit of the 80% confidence interval
for conditional power does not exceed 50%.
A formal interim analysis for safety will be conducted
beginning 1 year after enrollment and then every 6
months, to test whether the primary composite adverse
neonatal outcome is significantly worse in the insulin/
metformin group compared to the insulin/placebo group
using a Lan-DeMets α-spending function with Pocock
boundaries. Based on a one-sided alpha level of 0.025,
the DSMB may consider stopping the trial at any of the
six interim analyses if the p-value is < 0.007, correspond-
ing to worse composite neonatal outcome in the insulin/
metformin group. The DSMB will not evaluate for early
efficacy except as described above at 75%.
Analyses will be performed by an independent, un-
blinded study statistician and presented to the DSMB,
which will make recommendations regarding further
conduct of the trial. The DSMB charter will include
thresholds and rules for trial stoppage based on formal
safety, efficacy, and futility limits.
Table 4 Schedule of assessments and forms

















Screening, informed consent, inclusion,
exclusion, medical history, randomize
X
Dispense study agent X XXX
Dose escalation from 500mg
BID to 1000 mg BID
Xa Xa
Collect study bottle, pill count
of returned bottle
XXX X or plan
to obtain
Record total daily insulin dosing
(from enrollment through delivery)
X X X X X XXX X
Maternal side effects, symptoms,
episodes of hypoglycemia, adverse events
X X X X XXX X
Maternal serious adverse events X X X X XXX X X
Copy of glucose log XXX X or plan
to obtain
Maternal weight and blood pressure X XXX
Blood draw 24–30 weeks’
gestation
Maternal breastfeeding intention questionnaire 24–30 weeks’
gestation
Measure infant anthropometrics Within 72 h
of delivery
Collection of delivery and
neonatal outcomes
X X






a Dose is to be escalated at Day 7 and no later than Day 21 per subject’s study agent tolerance. Day 28, Day 35 and Day 42 contacts to occur only If indicated per
subject’s study agent tolerance. All study agent tolerance contacts can be via telephone or in-person (such as during regularly scheduled pre-natal visits)
b Study visits are to occur every 4 weeks during selected regularly scheduled pre-natal visits. Timing of study visits may vary based on the patient’s pre-natal visit
schedule, but study visits must occur at least once each 30 days
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Data analysis
Analyses will follow the intention-to-treat principle, in
which subjects will be analyzed within the group to
which they were randomized, regardless of whether they
received the assigned intervention or discontinued the
study agent prior to delivery. Primary analyses will be
based on the intention to treat population, which in-
cludes all randomized subjects who took at least one
dose of the study agent. In addition, a secondary analysis
of the primary outcomes will be completed for the
per-protocol population, defined as a subset of the
intention to treat population who took the assigned
double-blind study agent until the time of delivery with-
out any major protocol deviations. Major protocol devia-
tions include violations in inclusion and exclusion
criteria at enrollment and poor compliance with the
study drug, defined as subjects taking less than 50% of
the study drug. All major protocol deviations will be
identified in a blinded fashion prior to database lock.
Descriptive statistics, chi-square tests, and analysis of
variance will be used to characterize subjects enrolled and
randomized to determine comparability of the two inter-
vention groups at baseline for characteristics considered
prognostic for the primary outcome, such as maternal body
mass index (BMI), parity, and medical co-morbidities.
Primary outcome
Incidence of the primary outcome (i.e., composite adverse
neonatal outcome) will be compared between treatment
groups using logistic regression adjusting for study site,
timing of diabetes diagnosis (pre-existing versus during
pregnancy), gestational age at randomization (as a con-
tinuous measure), and baseline maternal BMI. Any sites
with low enrollment may be pooled for statistical analyses.
Odds ratio and 95% confidence interval will be calculated,
as well as the number needed to treat to prevent the com-
posite adverse neonatal outcome. Subjects who discon-
tinue from the study and therefore have unknown primary
outcomes will be considered as events. Statistical signifi-
cance is determined relative to p = 0.044, to adjust for the
formal interim analysis.
Sensitivity analysis of the primary outcome will include
the following: 1) a complete case analysis, excluding subjects
who discontinue from the study and therefore have an un-
known primary outcome; 2) multiple imputation of missing
values for the primary outcome, which assumes study
drop-outs are missing at random; and 3) control-based mul-
tiple imputation, in which missing values for the primary
events for the metformin arm are imputed based on the pla-
cebo event rates and analysis of the per-protocol population.
Additional analyses of the primary outcome
Pre-specified subgroup analyses will be conducted for
factors that may be related to the outcome measures,
including maternal BMI (obese versus non-obese),
gestational age at time of randomization (10–< 14 weeks,
14–< 18 weeks, 18–< 21 weeks), timing of diabetes diag-
nosis (pre-existing versus during pregnancy), and by
compliance level. Interaction tests will be used to deter-
mine whether the addition of metformin significantly
differs across subgroups, such as obesity (BMI > 30 kg/
m2) and reported compliance/adherence. P-values of
0.10 will be considered indicative of significant subgroup
differences.
Other analyses to assess treatment effectiveness,
adjusting for additional baseline patient characteristics
(covariates), will be conducted. The objectives of these
analyses are to estimate the influence of covariates on
the outcome and to use covariates to improve the esti-
mated difference between treatment groups. A stepwise
logistic regression model will be used to identify and es-
timate the effect of multiple prognostic factors on the
occurrence of the composite adverse neonatal outcome.
These analyses will be considered exploratory in nature
and will not be viewed as providing confirmatory tests of
hypotheses. Descriptive analyses will also evaluate treat-
ment group differences for each of the components of
the composite outcome.
Secondary outcomes
There are two key secondary outcomes: infant fat mass
(%), as measured by anthropometrics, and proportion of
subjects with clinically relevant maternal hypoglycemia,
defined as a CBG < 60, regardless of symptoms. Statis-
tical significance of the treatment group comparisons for
the key secondary outcomes will be evaluated in a
step-down fashion in order to preserve the study-wise
type 1 error rate. If the primary outcome is found statis-
tically significant (at p < 0.044), then infant fat mass will
be evaluated relative to p = 0.05. If found statistically sig-
nificant, then the incidence of maternal hypoglycemia
will be evaluated relative to p = 0.05. If any statistical test
in this order fails to reach statistical significance, subse-
quent parameters will not be evaluated for statistical
significance.
Analyses of all other secondary outcomes are consid-
ered exploratory in nature and will not be viewed as pro-
viding confirmatory tests of hypotheses. There will be
no adjustment for multiple comparisons of the explora-
tory secondary outcomes, and p-values will be provided
for descriptive purposes only.
Treatment groups will be compared for categorical sec-
ondary outcomes with logistic regression and for continu-
ous secondary outcomes with analysis of covariance
(ANCOVA). Variables that are not normally distributed
will be assessed via nonparametric ANCOVA. All analyses
will adjust for study site, timing of diabetes diagnosis
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(pre-existing versus during pregnancy), gestational age at
randomization, and maternal BMI.
Further logistic regression and ANCOVA models will
be used to identify and estimate the effect of multiple
prognostic factors on secondary outcomes. Interaction
tests will be used to determine whether the addition of
metformin significantly differs across subgroups, such as
obesity (BMI > 30 kg/m2), reported compliance/adher-
ence, and others.
Safety and adverse events
The steering committee and the DSMB are jointly respon-
sible for safety monitoring. Site principal investigators,
steering committee members, and/or their designated site
study staff will conduct medical monitoring for unantici-
pated problems (UPs), adverse events (AEs), and serious
adverse events (SAEs) and record and report them to their
institutional IRB. The study PI responsible for correspond-
ence will notify the DSMB, Federal Drug Administration
(FDA), and IRBs regarding UPs, AEs, and SAEs as
appropriate.
Detailed information concerning AEs and SAEs will be
collected and evaluated throughout the trial. The DCC
will report all AEs and SAEs to the DSMB. The DSMB
will review all AEs, SAEs, and other interim safety data
and will provide a report to the PIs and the IRBs. All
SAEs are to be entered into the data monitoring system
within 48 h of learning of the SAE.
Unanticipated problems involving risk to subjects or others
Any incident, experience, or outcome that meets all of the
following criteria will be considered a UP. If an event is
unexpected in nature, severity, or frequency (i.e., not
described in study-related documents, such as the
IRB-approved protocol or consent form, the investigators’
brochure, agent package insert, etc.) and if an event is re-
lated or possibly related to participation in the research
(i.e., possibly related means there is a reasonable possibil-
ity that the incident experience or outcome may have been
caused by the procedures involved in the research).
Maternal adverse events
An AE is an untoward medical occurrence, regardless of
whether it is considered study-related, that occurs dur-
ing the conduct of a clinical trial. Any change in clinical
status (e.g., routine labs, X-rays, physical examinations,
etc.) that is considered clinically significant by the study
investigator is considered an AE. Any condition respon-
sible for surgery will be documented as an AE if the con-
dition meets the criteria for an AE. Any AE that results
in hospitalization for 24 or more hours or prolonged
hospitalization will be documented and reported as an
SAE unless specifically instructed otherwise in this
protocol. However, hospital admission alone is not
automatically considered an AE. An AE does not include
the following: preterm delivery, defined as delivery > 23
through < 36 weeks 6 days’ gestation or maternal proce-
dures (e.g., surgery, endoscopy, tooth extraction) not re-
lated to the study. However, the condition that leads to
the procedure is considered an AE. An AE also does not
include pre-existing diseases or conditions present or de-
tected prior to the start of study agent administration that
do not worsen (e.g., hypertension, asthma, migraines) or a
woman who is hospitalized when enrolled or who under-
goes hospitalization or prolonged hospitalization for diag-
nostic or elective surgical procedures for a pre-existing
condition, social and/or convenience reasons, or for infant
delivery. AEs do not include overdose of either the study
agent or concomitant medication without any signs or
symptoms unless the subject is hospitalized for observa-
tion. Finally, the subject experiencing any event prior to
taking her first dose of study agent will not be considered
an AE.
Maternal serious adverse events
A serious AE is any AE for the mother that, as determined
by the investigator or the sponsor, results in death. A
life-threatening AE means that the study subject was, in
the opinion of the investigator or sponsor, at immediate
risk of death from the reaction as it occurred and required
immediate intervention. However, inpatient hospitalization,
prolongation of existing hospitalization, and maternal
hospitalization for infant delivery are not considered
reportable SAEs for this study. The definition of prolonga-
tion of an existing hospital stay includes maternal
hospitalization for infant delivery for longer than 7 days
and/or infant hospitalization for longer than maternal
hospitalization. Any event that would result in a persistent
disability. Any major congenital anomaly or birth defect in-
volving a major organ system (e.g., a heart or brain defect).
Minor congenital anomalies, such as choroid plexus cysts
or renal pelvis dilation, are not considered major birth de-
fects. An important medical event that may not result in
one of the above outcomes, but that may jeopardize the
health of the study participant or require medical or surgi-
cal intervention to prevent one of the outcomes listed in
the above definition of serious event.
Infant adverse events and serious adverse events
The definition of AE and SAE is the same for infants as
it is for mothers. Infant AEs and reportable SAEs for this
study are detailed in Table 5 and based on the Eunice
Kennedy Shriver National Institute of Child health and
Human Development (NICHD) Pediatric Trials Network
[14]. AEs that do not meet any of the criteria for serious
will be regarded as non-serious AEs.
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Adverse event reporting period
The study period during which AEs must be reported is
defined as the period from the initiation of any study
procedures to the end of the study treatment follow-up.
The study treatment follow-up period for the mother is
defined as until discharge from the hospital. For the in-
fant, the treatment follow-up period is through 30 days
of life. In addition, AEs and SAEs for the mother and in-
fant must be reported through 30 days after the last dose
of study agent.
A pre-existing condition is one that is present at the
start of the study. A pre-existing condition will be re-
corded as an AE if the frequency, intensity, or the char-
acter of the condition worsens during the study period.
Local site PIs will follow all unresolved AEs until the
events are resolved, the subject is lost to follow-up, the
subject is withdrawn from the study, or the AE is other-
wise explained. Subjects will be instructed to notify the
study staff at their local institution if they experience an
event that might be related to the study agent, even if it
occurs following completion of participation. Primary
clinicians will also be instructed to notify study staff if
their patient experiences an event that might be related
to the study agent.
There are no clinical laboratory tests performed as part
of this study, but clinical labs may be measured as stand-
ard care for the patient. A clinical laboratory abnormality
will be documented as an AE if the following conditions
are met: the laboratory abnormality is not refuted by a re-
peat test to confirm the abnormality and the abnormality
suggests a disease and/or organ toxicity that requires ac-
tive management, such as discontinuation of the study
agent, more frequent follow-up assessments, or further
diagnostic evaluation and management.
Reporting of serious adverse events and unanticipated
problems
MPIs and local site PIs will conform to the reporting
timelines, formats, and requirements of the various en-
tities to which they are responsible. For any maternal,
fetal, or neonatal deaths or other life-threatening events,
they will notify immediately (within 24 h of the site
learning of the death) and enter as much information
onto the SAE form as can be completed. A copy of the
patient’s medical record pertaining to the event should
be made and a death certificate requested, when avail-
able. If an autopsy is performed, a copy of the report
should be collected as well. All sites need to report devi-
ations per their site IRB protocol.
Sponsor reporting: Notifying the FDA
The contact PI is required to report certain study events
in an expedited fashion to the FDA. These written notifi-
cations of adverse events are referred to as the Investiga-
tional New Drug (IND) safety reports. The following
describes the safety reporting requirements, by timeline,
for reporting and associated type of event based on the
date that the data was entered into the online data entry
system if it is uncommon and strongly associated with
study agent exposure otherwise once determined to qual-
ify for reporting by the study coordinator. Any study event
that meets SAE requirements, is determined to be related
to the study agent, is unexpected (as defined under IND
reporting requirements), is fatal or life-threatening (as
Table 5 Infant outcomes based on the Pediatric Trials Network




NEC Bell stage II or III
Perforation with intra-abdominal
















intervention (e.g. chest tube,
nitric oxide, milrinone, sildenafil)
Neurological
Seizure, no medical treatment
Intraventricular hemorrhage
(IVH) grade I or II
Seizure requiring medical
treatment

















Wound infection requiring topical
treatment only
Other infection proven by






Retinopathy or prematurity (ROP),
any stage not requiring treatment
Conjunctivitis requiring systemic
intervention or treatment
ROP, Any stage requiring
surgical or medical treatment
Otolaryngology
Hearing impairment Confirmed hearing loss,
unilateral or bilateral
Miscarriage
Pregnancy loss < 12 weeks, 0 days
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defined under IND reporting requirements), or a previous
adverse event that was not initially deemed reportable but
is later found to fit the criteria for reporting must be re-
ported within 7 days. Any study event that meets SAE re-
quirements and is uncommon and known to be strongly
associated with exposure to the study agent, determined
to be related to the study agent, is unexpected (as defined
by IND reporting requirements), is serious (as defined
under IND reporting requirements) but not fatal or
life-threatening, or a previous adverse event that was not
initially deemed reportable but is later found to fit the cri-
teria for reporting will be reported within 15 days.
Stopping rules
Study stopping rules will be based on DSMB review. In-
dividual stopping rules include delivery and maternal
side-effects that cannot be managed with oral medica-
tion. However, data collection will continue through
study completion (30 days following last dose of study
agent for mother and 30 days after delivery for infant) to
ascertain maternal and infant outcomes.
Medical monitoring
Each site PI will oversee the safety of the study at his/
her site. This safety monitoring will include careful as-
sessment and appropriate reporting of AEs as noted
above, as well as the construction and implementation
of a site data- and safety-monitoring plan. Medical mon-
itoring includes a regular assessment of the number and
type of serious AEs. If a subject develops an SAE, the
subject’s obstetric care provider, in collaboration with
the site PI and the trial unblinded medical monitor, will
ascertain the safety of continuing the intervention.
Unblinded MedicaI monitor
The trial has a designated unblinded medical monitor
who is otherwise uninvolved with the study and not a
member of the DSMB. The medical monitor will review
each reported SAE to evaluate the PI’s assessment of the
relationship to the study agent and expectedness and to
ensure that the site PI follows the patient appropriately.
In cases of emergency, unblinding materials will be
made available to the unblinded medical monitor or a
study PI if the unblinded medical monitor is not avail-
able. The medical monitor can share unblinded informa-
tion about the study agent with other healthcare
professionals, including the site PI, if unblinding of the
site PI is determined necessary by the study PI and the
medical monitor.
Independent data safety monitoring board
An independent DSMB will provide oversight to ensure
that the trial accrues at a sufficient rate and that the
safety and privacy of all study subjects is protected.
DSMB members are not involved in any aspect of the
trial operation. The DSMB will function under a charter
that specifies guidelines for operation. Detailed informa-
tion concerning adverse events will be collected and
evaluated throughout the conduct of the trial. The
DSMB will review all treatment-emergent adverse
events, all SAEs, and other interim safety data, and will
provide a report of recommendations to the steering
committee and to the local IRBs.
In addition to SAE review by the unblinded medical
monitor, the DSMB will receive a monthly update of
SAEs and a periodic full report of safety data per DSMB
decision to review study progress, to monitor the con-
duct of the study for safety concerns, and to conduct the
formal interim analyses for efficacy, futility, and safety
analysis. The DSMB will make recommendations about
the conduct of the study for safety concerns. The DSMB
could recommend to continue the study, suggest a
protocol modification, temporarily halt enrollment to
allow further safety investigation, or to end the study
early. To maintain the blind for the entire study team,
an independent statistical analysis team at the CSCC will
produce the closed session report with unmasked treat-
ment groups. Closed reports will be maintained behind a
firewall, with access allowed only to the unblinded team.
Discussion
The MOMPOD study will provide high quality, contem-
porary evidence for management of overt T2DM com-
plicating pregnancy to improve neonatal outcomes. This
study has the potential to change medical management
of women with overt T2DM and pregnancy not only in
the United States but also globally since metformin is
cost-effective and tolerated well in nonpregnant women.
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